| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/21/2013 | US20130045247 Fatty acid conjugates of quetiapine, process for making and using the same |
| 02/21/2013 | US20130045245 Apixaban formulations |
| 02/21/2013 | US20130045243 NANOGENOMICS FOR MEDICINE: siRNA ENGINEERING |
| 02/21/2013 | US20130045238 Emulsions for transdermal delivery |
| 02/21/2013 | US20130045229 Anti-Viral Compounds |
| 02/21/2013 | US20130045223 Methods and compositions to protect aquatic invertebrates from disease |
| 02/21/2013 | US20130045217 Lipidomic biomarkers for atherosclerosis and cardiovascular disease |
| 02/21/2013 | US20130045214 P53 modulator and cancer target |
| 02/21/2013 | US20130045212 Biological Materials and Uses Thereof |
| 02/21/2013 | US20130045204 Fluorinated bisphenol ether compounds and methods for their use |
| 02/21/2013 | US20130045203 Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP |
| 02/21/2013 | US20130045194 Delivery of Cholesteryl Ester to Steroidogenic Tissues |
| 02/21/2013 | US20130045193 Compositions and methods for the prevention of cardiovascular disease |
| 02/21/2013 | US20130045192 Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders |
| 02/21/2013 | US20130045188 Reduction of tgf beta signaling in myeloid cells in the treatment of cancer |
| 02/21/2013 | US20130045186 Method of Detecting and/or Identifying Adeno-Associated Virus (AAV) Sequences and Isolating Novel Sequences Identified Thereby |
| 02/21/2013 | US20130045183 Boswellia oil, its fractions and compositions for enhancing brain function |
| 02/21/2013 | US20130045179 Combination therapy and methods for treatment and prevention of hyperproliferative diseases |
| 02/21/2013 | US20130045177 Method for Inhibition of Potential-Dependent Cation Channel |
| 02/21/2013 | US20130045175 Use of Skin Permeation and Retention Enhancer Compound in Cosmetic and Pharmaceutical Compositions and Cosmetic and Pharmaceutical Products Containing Said Compound |
| 02/21/2013 | US20130045174 Use of indole compounds as a cosmetic |
| 02/21/2013 | US20130045172 USE OF CIS-EPOXYEICOSATRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO TREAT CONDITIONS MEDIATED BY PBR, CB2, and NK2 RECEPTORS |
| 02/21/2013 | US20130045171 Bonding tissues and cross-linking proteins with naphthalimide compounds |
| 02/21/2013 | US20130045169 Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| 02/21/2013 | US20130045165 4-fluoro-4-arylpiperdin-1-yl derivatives as mu opioid function moderators |
| 02/21/2013 | US20130045162 Delivery system for specifically targeting cancer cells and method of use thereof |
| 02/21/2013 | DE102011110909A1 Zusammensetzungen mit einer die Hautbarriere verbessernden Wirkstoffkombination Compositions with the skin barrier-enhancing drug combination |
| 02/21/2013 | CA2846213A1 Methods for ameliorating symptoms or conditions caused by stress |
| 02/21/2013 | CA2846041A1 Process for manufacturing hmb and salts thereof |
| 02/21/2013 | CA2845634A1 Abuse-resistant mucoadhesive devices for delivery of buprenorphine |
| 02/21/2013 | CA2845630A1 Amino quinazolines as kinase inhibitors |
| 02/21/2013 | CA2845553A1 Tenofovir alafenamide hemifumarate |
| 02/21/2013 | CA2845496A1 Novel compound isolated from quamoclit, and composition for preventing or treating diabetes containing the compound as an active ingredient |
| 02/21/2013 | CA2845391A1 Soluble polypeptides |
| 02/21/2013 | CA2845301A1 Combinations of corroles and statins |
| 02/21/2013 | CA2845284A1 Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (cetp) inhibitors |
| 02/21/2013 | CA2845250A1 Salt and polymorph of pyrazolopyrimidinone compound, and pharmaceutical composition containing the same, preparation method and use thereof |
| 02/21/2013 | CA2845228A1 Controlled-release formulation |
| 02/21/2013 | CA2845118A1 Steroid hormone delivery systems and methods of preparing the same |
| 02/21/2013 | CA2845039A1 Combinations of a 5-ht4 receptor agonist and a pde4 inhibitor for use in therapy |
| 02/21/2013 | CA2845030A1 Piperazine derivatives |
| 02/21/2013 | CA2844985A1 Tricyclic compounds as anticancer agents |
| 02/21/2013 | CA2844982A1 Lysophosphatidic acid receptor antagonists |
| 02/21/2013 | CA2844944A1 Pharmaceutical aerosol product for administration by oral or nasal inhalation |
| 02/21/2013 | CA2844930A1 Compositions and methods for inducing apoptosis |
| 02/21/2013 | CA2844907A1 Concentrated felbamate formulations for parenteral administration |
| 02/21/2013 | CA2844827A1 Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions |
| 02/21/2013 | CA2844799A1 Heteroaryl sodium channel inhibitors |
| 02/21/2013 | CA2844794A1 Heterocyclic derivative and pharmaceutical |
| 02/21/2013 | CA2844783A1 Substituted 2-imidazolidinones and 2-imidazolones and their use in the treatment of cancer |
| 02/21/2013 | CA2844750A1 Method for preparing nucleic acid aptamer |
| 02/21/2013 | CA2844497A1 5-fluoro-4-imino-3-(substituted)-3,4-dihydropyrimidin-2-(1h)one derivatives |
| 02/21/2013 | CA2844091A1 Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections |
| 02/21/2013 | CA2843881A1 Sustained release composition of prostacyclin |
| 02/21/2013 | CA2843537A1 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo [4,5-c] quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor |
| 02/21/2013 | CA2843502A1 Therapeutic methods |
| 02/21/2013 | CA2843499A1 Indazole compounds, compositions and methods of use |
| 02/21/2013 | CA2843474A1 A novel 1,2,3,4-tetrahydroquinoline derivative useful for the treatment of diabetes |
| 02/21/2013 | CA2843100A1 Funny current (if) inhibitors for use in a method of treating and preventing heart failure in feline |
| 02/21/2013 | CA2841801A1 Inhibitors of bruton's tyrosine kinase |
| 02/21/2013 | CA2841549A1 Taste masked pharmaceutical composition |
| 02/21/2013 | CA2841458A1 Tricyclic heterocyclic compounds and jak inhibitors |
| 02/21/2013 | CA2841037A1 Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease |
| 02/21/2013 | CA2841012A1 Sweet flavor modifier |
| 02/21/2013 | CA2840030A1 Novel compounds for the treatment of inflammatory bowel disease |
| 02/21/2013 | CA2839647A1 Folate conjugates of albumin-binding entities |
| 02/21/2013 | CA2839529A1 Edible composition comprising sterol |
| 02/21/2013 | CA2838784A1 Pyrazolo[3,4-c]pyridine compounds and methods of use |
| 02/21/2013 | CA2827887A1 No- and h2s-releasing compounds |
| 02/20/2013 | EP2560001A2 Compositions and methods related to protein displacement therapy for myotonic distrophy |
| 02/20/2013 | EP2559762A1 Novel anti-hsp90 monoclonal antibody |
| 02/20/2013 | EP2559694A2 Azaindoles useful as inhibitors of Janus kinases |
| 02/20/2013 | EP2559693A1 Polycyclic compound |
| 02/20/2013 | EP2559692A1 Thiophene analogues for the treatment or prevention of Flavivirus infections |
| 02/20/2013 | EP2559691A1 Thiophene analogues for the treatment or prevention of Flavivirus infections |
| 02/20/2013 | EP2559690A1 Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
| 02/20/2013 | EP2559689A1 Preparation process for crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]benzoic acid |
| 02/20/2013 | EP2559686A1 Therapeutic quinoline and naphthalene derivatives |
| 02/20/2013 | EP2559685A1 Fentanyl derivatives as pH-dependent opioid receptor agonists |
| 02/20/2013 | EP2559455A1 Heteroaryl derivatives as DGAT1 inhibitors |
| 02/20/2013 | EP2559442A1 Method for regulating microrna content in organisms and uses thereof |
| 02/20/2013 | EP2559435A1 Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke |
| 02/20/2013 | EP2559434A2 Treatment of COPD using a histidine decarboxylase inhibitor sole or combined with an anti-H1 drug or with a leucotriene receptor antagonist |
| 02/20/2013 | EP2559433A1 Composition for lowering blood lipid and elevating high-density lipoprotein and method for manufacturing the same |
| 02/20/2013 | EP2559432A1 Means for the prophylaxis and treatment of acute and chronic pancreatitis |
| 02/20/2013 | EP2559431A1 Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide |
| 02/20/2013 | EP2559429A2 Anticancer drug delivery system using ph-sensitive metal nanoparticles |
| 02/20/2013 | EP2559428A1 Micronized opioid compositions and dosage forms and methods of making same |
| 02/20/2013 | EP2558866A1 Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors |
| 02/20/2013 | EP2558565A1 Fuel and chemical production from oleaginous yeast |
| 02/20/2013 | EP2558506A2 Tissue targeting |
| 02/20/2013 | EP2558477A1 Analogues of etoposide for the treatment of tumours |
| 02/20/2013 | EP2558475A1 Pyrrolobenzodiazepines used to treat proliferative diseases |
| 02/20/2013 | EP2558474A1 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
| 02/20/2013 | EP2558469A1 Pyrrolopyrazinone inhibitors of kinases |
| 02/20/2013 | EP2558468A1 5, 7-substituted-imidazo [1, 2-c]pyrimidines as inhibitors of jak kinases |
| 02/20/2013 | EP2558467A1 Aryl - /heteroaryl - cyclohexenyl - tetraazabenzo [e]azulenes as vasopressin antagonists |
| 02/20/2013 | EP2558466A2 Phosphonates with reduced toxicity for treatment of viral infections |
| 02/20/2013 | EP2558465A1 Tricyclic pyridyl-vinyl pyrroles as par1 inhibitors |
| 02/20/2013 | EP2558464A1 Azacyclic spiroderivatives as hsl inhibitors |